NEW YORK (360Dx) – The US Food and Drug Administration said on Wednesday that it has granted marketing clearance for the Ansh Labs PicoAMH ELISA diagnostic test as an aid in determining a patient’s menopausal status.

The agency granted clearance of the Webster, Texas-based company's test through the de novo premarket review regulatory pathway for low-to-moderate-risk devices of a new type.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.